help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-1562
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arturi, F.
Right arrow Articles by Filetti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arturi, F.
Right arrow Articles by Filetti, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Hazardous Substances DB
*ESTRADIOL
*OXYTOCIN
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 4 2321-2326
Copyright © 2005 by The Endocrine Society

Regulation of Iodide Uptake and Sodium/Iodide Symporter Expression in the MCF-7 Human Breast Cancer Cell Line

Franco Arturi1, Elisabetta Ferretti1, Ivan Presta, Tiziana Mattei, Angela Scipioni, Daniela Scarpelli, Rocco Bruno, Ludovic Lacroix, Emanuele Tosi, Alberto Gulino, Diego Russo and Sebastiano Filetti

Dipartimento di Medicina Sperimentale e Clinica (F.A., I.P., D.S.) and Dipartimento di Scienze Farmacobiologiche (D.R.), Università di Catanzaro, "Magna Graecia," 88100 Catanzaro, Italy; Dipartimento di Medicina Sperimentale e Patologia (E.F., A.G.) and Dipartimento di Scienze Cliniche (T.M., A.S., E.T., S.F.), Università "La Sapienza," 00161 Roma, Italy; Tinchi Pisticci Hospital (R.B.), 75020 Matera, Italy; and Department of Clinical Biology (L.L.), Institut Gustave-Roussy, 94805 Villejuif Cedex, France

Address all correspondence and requests for reprints to: Sebastiano Filetti, M.D., Università degli Studi di Roma La Sapienza, Dipartimento di Scienze Cliniche, Clinica Medica 2, Viale del Policlinico, 155, 00161 Roma, Italy. E-mail: sebastiano.filetti{at}uniroma1.it.

Sodium/iodide symporter (NIS) expression has recently been described in human breast cancer, with emphasis on its potential exploitation for the treatment of these tumors with radioiodine. In this study, we analyzed the regulation of NIS expression and function in the MCF-7 human breast cancer cell line. Cell exposure to insulin, IGF-I, IGF-II, or prolactin induced significant increases in 125I uptake and the expression of both NIS mRNA and NIS protein. The latter increases were evident after 6 and 12 h of hormonal stimulation, respectively. In immunocytochemistry studies, NIS was detected mainly in the plasma membrane of MCF-7 cells. A low but significant increase in iodide uptake was produced by treatment with activators of the adenylyl cyclase (cAMP) or protein kinase C pathways. Our study demonstrates that: 1) MCF-7 breast cancer cells are capable of active iodide transport that can be stimulated by insulin, IGF-I, IGF-II, or prolactin; 2) both NIS transcript and protein are expressed in these cells, and this expression is also hormonally stimulated; and 3) MCF-7 iodide transport and NIS expression may be influenced by the activation of cAMP or protein kinase C-dependent signaling. These findings increase our understanding of the molecular mechanisms that regulate NIS expression in breast cancer cells, information that is fundamental for future research aimed at the development of targeted radioiodide treatment for this type of cancer.




This article has been cited by other articles:


Home page
JNMHome page
K.-H. Jung, J.-Y. Paik, B.-H. Ko, and K.-H. Lee
Mitogen-Activated Protein Kinase Signaling Enhances Sodium Iodide Symporter Function and Efficacy of Radioiodide Therapy in Nonthyroidal Cancer Cells
J. Nucl. Med., December 1, 2008; 49(12): 1966 - 1972.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Kogai, E. Ohashi, M. S. Jacobs, S. Sajid-Crockett, M. L. Fisher, Y. Kanamoto, and G. A. Brent
Retinoic Acid Stimulation of the Sodium/Iodide Symporter in MCF-7 Breast Cancer Cells Is Meditated by the Insulin Growth Factor-I/Phosphatidylinositol 3-Kinase and p38 Mitogen-Activated Protein Kinase Signaling Pathways
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1884 - 1892.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
T Kogai, K Taki, and G A Brent
Enhancement of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
O. Dohan, A. De la Vieja, and N. Carrasco
Hydrocortisone and Purinergic Signaling Stimulate Sodium/Iodide Symporter (NIS)-Mediated Iodide Transport in Breast Cancer Cells
Mol. Endocrinol., May 1, 2006; 20(5): 1121 - 1137.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Puppin, F. D'Aurizio, A. V. D'Elia, L. Cesaratto, G. Tell, D. Russo, S. Filetti, E. Ferretti, E. Tosi, T. Mattei, et al.
Effects of Histone Acetylation on Sodium Iodide Symporter Promoter and Expression of Thyroid-Specific Transcription Factors
Endocrinology, September 1, 2005; 146(9): 3967 - 3974.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society